Mackie - July 2ndOn Thursday, Uddin reiterated his “Speculative Buy” rating and $8.70 target price for Acasti, representing a projected 12-month return of 469 per cent at the time of publication.
“ACST has a strong looking chart as the stock has consolidated for three years. Volume has now picked up – the stock has moved out of its triangle formation. We expect ACST to have a good run into Phase III results,” says Uddin.
https://www.cantechletter.com/2019/07/time-to-hop-on-board-acasti-pharma-says-mackie-research/